SPECT neuroimaging in translational research of CNS disorders

Neurochemistry International

Volumn 52, Issue 3, 2008, Pages 352-362

  Sharma, Sushil ^a   Ebadi, Manuchair ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cerebral blood flow; CNS disorders; Dopamine; Drug addiction; Gene manipulated mice; MicroPET imaging; Parkinson's disease; Serotonin; Spatial resolution; SPECT CT imaging

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ACETYLSALICYLIC ACID; AMILORIDE; CONTRAST MEDIUM; CYSTEINE ETHYL ESTER TC 99M; DOPAMINE; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDINAVIR; IODINE 123; IODOBENZAMIDE I 123; IODONITROQUIPAZINE I 123; IODOQUINUCLIDINYL BENZYLATE I 123; IOMAZENIL I 123; METHAMPHETAMINE; METHYLPHENIDATE; NEUROTRANSMITTER; RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN BLOOD FLOW; BRAIN REGION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC SYSTEM; COCAINE DEPENDENCE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC ANALYSIS; HUMAN; INTERMETHOD COMPARISON; NERVE DEGENERATION; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; REPORTER GENE; SEROTONINERGIC SYSTEM; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BIOMEDICAL RESEARCH; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SUBSTANCE ABUSE DETECTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

ANIMALIA; MUS;

EID: 38049090555     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.08.011     Document Type: Short Survey

References (88)

1. Abou-Saleh M.T. Neuroimaging in psychiatry: an update. J. Psychosom. Res. 61 (2006) 289-293
2. Ajjimaporn A., Swinscoe J., Shavali S., and Ebadi M. Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells. Brain Res. Bull. 67 (2005) 466-475
3. Antonini A., and DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med. 5 (2004) 201-206
4. Bastos Leite A.J., Scheltens P., and Barkhof F. Pathological aging of the brain: an overview. Top. Magn. Reson. Imaging 15 (2004) 369-389
5. Belanger H.G., Vanderploeg R.D., Curtis G., and Warden D.L. Recent neuroimaging techniques in mild traumatic brain injury. J. Neuropsychiatr. Clin. Neurosci. 19 (2007) 5-20
6. Brady L. Neuroimaging Consortium Workshop: development of novel PET and SPECT ligands for brain imaging. J. Clin. Pharmacol. Suppl. (2001) 116S-117S
7. Bremer J.D. Functional neuroimaging in post-traumatic stress disorder. Exp. Rev. Neurother. 7 (2007) 393-405
8. Brockhuis B. Cerebral blood flow changes in patients with dementia with Lewy bodies (DLB). A study of 6 cases. Nucl. Med. Rev. Cent. East Eur. 9 (2006) 114-118
9. Broderick D.F. Neuroimaging in neuropsychiatry. Psychiatr. Clin. N. Am. 28 (2005) 549-566
10. Brust P., Scheffel U., and Szabo Z. Radioligands for the study of the 5-HT transport in vivo. Drugs 2 (1999) 129-145
11. Cowan R.L. Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl) 189 (2007) 539-556
12. Cunha P.J., and Novaes M.A. Neurocognitive assessment in alcohol abuse and dependence: implications for treatment. Rec. Bras. Psiquiatr. 26 (2004) S23-S27
13. de Mendelssohn A., Kasper S., and Tauscher J. Neuroimaging in substance abuse disorders. Nervenarzt 75 (2004) 651-662
14. Decata A., Intiso D., Bernal M., Molinaro F., Mazzoccoli G., D'Alessandro V., Greco A., Curci S., Sperandeo M., Frusciante V., Fanularo G., Dallapiccola B., and Vendemiale G. Int. J. Immunopathol. Pharmacol. 20 (2007) 91-96
15. Dou H., Destache C.J., Morehead J.R., Mosley R.L., Boska M.D., Kinsley J., Gorantla S., Poluektova L., Nelson J.A., Chaubal M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Development of a macrophage-based nanoparticle plateform for antiretroviral drug delivery. Blood 108 (2006) 2827-2835
16. Dou H., Morehead J., Destache C.J., Kingsley J.D., Shlyakhtenko L., Zhou Y., Chaubai M., Werling J., Kipp J., Rabinow B.E., and Gendelman H.E. Laboratory investigations for the morphologic, pharmacokinetic, and anti-reteroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358 (2007) 148-158
17. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., and Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
18. Ebadi M., and Sharma S. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson's disease. J. Exp. Biol. Med. 231 (2006) 1576-1583
19. Ebadi M., Brown-Borg H., Garrett S., Singh B., Shavali S., and Sharma S. Metallothionein-mediated neuroprotection in genetically-engineered mice models of Parkinson's disease and aging. Mol. Brain Res. 134 (2005) 67-75
20. Ebadi M., Sharma S., Ghafourifar P., Brown-Borg H., and Refaey H.El. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods Enzymol. 396 (2005) 276-298
21. Elkashef A., and Vocci F. Biological markers of cocaine addiction: implications for medications development. Addict. Biol. 8 (2003) 123-139
22. Ernst M., Kimes A.S., and Jazbec S. Neuroimaging and mechanisms of drug abuse: interface of molecular imaging and molecular genetics. Neuroimaging Clin. N. Am. 13 (2003) 833-840
23. 99mTc-HMPAO SPECT. J. Gerontol. A: Biol. Sci. Med. Sci. 61 (2006) 1294-1299
24. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., and Houle S. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47 (2003) 123-133
25. Gotschalk P.C., and Kosten T.R. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend. 68 (2002) 95-104
26. Gottschalk P.C., and Kosten T.R. Isradipine enhancement of cerebral blood flow in abstinent cotain abusers with and without chronic perfusion deficits. Am. J. Addict. 11 (2002) 200-208
27. Gottschalk P.C., and Kosten T.R. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend. 68 (2002) 95-104
28. 18F]fluoro-A-8530, a high affinity ligand for alpha4beta-2 nicotinic acetylcholine receptors. Synapse 55 (2005) 89-97
29. Halldin C., Gulyas B., Langer O., and Farde L. Brain radioligands-state of the art and new trends. Quart. J. Nucl. Med. 45 (2001) 139-152
30. Hamano T., Tsuchida T., Hirayama M., Fujiyama J., Mutoh T., Yonekura Y., and Kuriyama M. Dopamine transporter SPECT in patients with Parkinson's disease. Kaku Igaku 37 (2000) 125-129
31. Huang Y., Hwang D.R., Bae S.A., Sudo Y., Guo N., Zhu Z., Narendran R., and Laruelle M. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)thenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl. Med. Biol. 31 (2004) 543-556
32. Hummerich R., Reischl G., Ehrlichmann W., Machulla H.J., Heinz A., and Schloss P. DASB-in vitro binding characteristics on human recombinant monoamine transporters with regards to its potential as positron emission tomography (PET) tracer. J. Neurochem. 90 (2004) 1218-1226
33. Iyo M., Sekine Y., and Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann. N.Y. Acad. Sci. 1025 (2004) 288-295
34. Jia S.W., Wang W., Liu Y., and Wu Z.M. Neuroimaging studies of brain corpus striatum changes among heroin-dependent patients treated with herbal medicine. U'finer Capsule. Addict. Biol. 10 (2005) 293-297
35. Johnson B., Barron B., Fang B., Lamki L., Wagner L., Wells L., Kenny P., Overton D., Dhother S., Abramson D., Chen R., and Kramer L. Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study. Psychopharmacology 136 (1998) 335-341
36. Johnson B.A., Devous M.D., Ruitz P., and Ait-Daoud N. Treatment advances for cocaine ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. Am. J. Psychiatr. 158 (2001) 1191-1198
37. Johnson B.A., Roaches J.D., Ait-Daoud N., Wells L.T., and Mauldin J.B. Effects of israpidine on cocaine-induced subjective mood. J. Clin. Psychopharmacol. 24 (2004) 180-191
38. Johnson B.A., Wells L.T., Roache J.D., Wallace C., Ait-Daoud N., and Wang Y. Israpidine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies. Am. J. Hypertens. 18 (2005) 813-822
39. Kegeles L.S., and Mann J.J. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology 17 (1997) 293-307
40. Kim S.E., Lee W.Y., Choe Y.S., and Kim J.H. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol. Res. 21 (1999) 255-261
41. Kimberley T.J., and Lewis S.M. Understanding neuroimaging. Phys. Ther. 87 (2001) 670-683
42. 10. Neurochem. Res. 31 (2006) 303-311
43. 99mTc-HMPAO SPECT scans in symptomatic neonates exposed to cocaine. J. Clin. Neurol. 9 (1994) 278-283
44. Kosten T.R. Pharmacology of cerebral ischemia in cocaine dependence. Drug Alcohol Depend. 49 (1998) 133-144
45. Kosten T.R., Gottschalk P.C., Tucker K., Rinder C.S., Dey H.M., and Rinder H.M. Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. Drug Alcohol Depend. 71 (2003) 187-194
46. Krause K.H., Dresel S.H., Krause J., La Fougere C., and Ackenhell M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 27 (2003) 605-613
47. Langstrom B., Andren P.E., Lindhe O., Svedberg M., and Hall H. In vitro techniques in neurodegenerative diseases. Mol. Imaging Biol. 9 (2007) 161-175
48. Lin K.J., Liu C.Y., Wey S.P., Hsiao I.T., Wu J., Fu Y.K., and Yen T.C. Brain SPECT imaging and whole-body biodistribution with [(123)I]ADAM-a serotonin transporter radiotracer in healthy human subjects. Nucl. Med. Biol. 33 (2006) 193-202
49. Lingford-Hughes A. Human brain imaging and substance abuse. Curr. Opin. Pharmacol. 5 (2005) 42-46
50. Lingford-Hughes A.R., Davies S.J., McIver S., Williams T.M., Daglish M.R., and Nutt D.J. Addiction. Br. Med. Bull. 65 (2003) 209-222
51. MacLaren D.C., Toyokuni T., Cherry S.R., Barrio J.R., Phelps M.E., Herschman H.R., and Ghambhir S.S. PET imaging in transgene expression. Biol. Psychiatr. 48 (2000) 337-348
52. Maharajan P., Maharajan V., Ravagnan G., and Paino G. The weaver mutant mouse: a model to study the ontogeny of dopamine transmission system and their role in drug addiction. Prog. Neurobiol. 64 (2001) 269-276
53. Mann K., Ackermann K., Croissant B., Mundle G., Nakovics H., and Dielh A. Neuroimaging of gender differences in alcohol dependence are women more vulnerable?. Alcohol Clin. Exp. Res. 29 (2005) 896-901
54. Mann K., Mundle G., Strayle M., and Wakat P. Neuroimaging in alcoholism: CT and MRI and clinical correlates. J. Neural Transm. 99 (1995) 145-155
55. Masters C.L., Cappai R., Barhham K.J., and Villmagne V.L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J. Neurochem. 97 (2006) 1700-1725
56. McConathy J., Kilts C.D., and Goodman M.M. Radioligands for PET and SPECT imaging of the central noradrenergic system. CNS Spectr. 6 (2001) 704-709
57. Moreno-Iniguez M., Ortuno F., Bonelli R.M., Millan M., Soutullo C.A., and Cervera-Enguiz S. Perseverative error in schizophrenia: correlation with cortical blood flow by SPECT. Actas Esp. Psiquiar. 35 (2007) 20-28
58. Moroz M.A., Sergonova I., Zanzonico P., Ageyeva L., Beresten T., Dyonima E., Burnazi E., Finn R.D., Doubrovin M., and Blasberg R.G. Imaging hNET reporter gene expression with 124I-MIBG. J. Nucl. Med. 48 (2007) 827-836
59. Nikolaus S., Wirrwar A., Antke C., Arkian S., Schramm N., Muller H.W., and Larisch R. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 308-313
60. Nikolaus S., Antke C., Beu M., Kley K., Larisch R., Wirrwar A., and Muller H.W. In vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT. Nucl. Med. Commun. 28 (2007) 207-213
61. 123I] Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine-an in vivo imaging study with a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 1305-1310
62. Nordahl T.E., Salo R., natusaki Y., Galloway G.P., Waters C., Moore C.D., Kile S., and Buonocore M.H. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatr. 62 (2005) 444-452
63. O'Carroll R. Neuropsychological and neuroimaging aspects of latent hepatic encephalopathy (LHE). Alcohol Alcohol. Suppl. 2 (1993) 191-195
64. 123I-QNB SPECT. J. Neurol. 14 (2007) (AHP)
65. Pimlott S.L. Radiotracer development in psychiatry. Nucl. Med. Commun. 26 (2005) 183-188
66. Ponomarev V., Doubrovin M., Serganova I., Vider J., Shavrin A., Beresten T., Ivanova A., Ageyeva L., Tourkova V., Balatoni J., Bornmann W., Blasberg R., and Gelovani Tjuvajev J. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 740-751
67. Ponomarev V., Doubrovin M., Shavrin A., Sergonova I., Beresten T., Ageyeva L., Cai C., Balatoni J., Alauddin M., and Gelovani J. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J. Nucl. Med. 48 (2007) 819-826
68. Ray P., Tsein R., and Ghambhir S.S. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res. 67 (2007) 3085-3093
69. Reneman L., de Win M.M., van den Brink W., Booij J., and den Heeten G.J. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Psychopharmacol. 20 (2006) 164-175
70. Schlaepfer T.E., Strain E.C., Greenberg B.D., Preston K.L., Lancaster E., Bigelow G.E., Barta P.E., and Pearlson G.D. Site of opioid action in the human brain: mu and kappa agonists subjective and cerebral blood flow effects. Am. J. Psychiatr. 155 (1998) 470-473
71. Schuh-Hofer, S., Richter, M., Geworski, L., Villringer, A., Israel, H., Wenzel, R., Munz, D.L., Arnold, G., 2007. Increased serotonin transporter availability in the brain stem of migraineurs. J. Neurol. (AHP).
72. 18F-DOPA in weaver mutant mice. Mol. Brain Res. 139 (2005) 23-30
73. Sharma S., Krause G., and Ebadi M. Radiation safety and quality control in the cyclotron laboratory. Radiat. Protect. Dosimetry 118 (2006) 431-439
74. 10. Brain Res. Bull. 70 (2006) 22-32
75. Shih M.C., Felicio A.C., deOliveira Godeiro-Junior C., de Carvalho Aguiar P., de Andrade L.A., Ferraz H.B., and Bressan R.A. Molecular imaging in hereditary forms of Parkinsonism. Eur. J. Neurol. 14 (2007) 359-368
76. Shimazono Y., and Matsushima E. Behavioral and neuroimaging studies on schizopherenia in Japan. Psychiatr. Clin. Neurosci. 49 (1995) 3-11
77. Smith D.F., and Jacobson S. Stereoselective neuroimaging in vivo. Eur. Neuropsychopharmacol. 7 (2007) 507-522
78. Stratone A., Stratone C., and Topoliceanu F. The neurotransmitters and alcohol dependence. Rev. The neurotransmitters and alcohol dependence. Rev. Med. Chir. Soc. Med. Nat. Lasi. 107 (2003) 136-231
79. Strickland T.L., Miller B.L., Kowell A., and Stein R. Neurobiology of cocaine-induced organic brain impairment: contributions from functional neuroimaging. Neuropsychol. Rev. 8 (1998) 1-9
80. Sugihara G., Ouchi Y., Nakamura K., Sekine Y., and Mori N. Advances in neuroimaging research of Asperger syndrome. Nippon Rinsho 65 (2007) 449-452
81. Szekeres G., Pavics L., and Janka Z. Investigation of the dopamine dysregulation hypothesis of schizopherenia with neuroimaging techniques. Ideggyogy Sz. 55 (2002) 226-232
82. Tian Y., Liu H., and Shi P. Simultaneous reconstruction of tissue attenuation and radioactivity maps in SPECT. Med. Imag. Comput. Comput. Assist. Interv. Int. Conf. Med. Image 9 (2006) 397-404
83. Van Dyck, C.H., Avery, R.A., Macavoy, M.G., Marek, K.L., Quinlan, D.M., Baldwin, R.M., Seibyl, J.P., Innis, R.B., Arnsten, A.F., 2007. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol. Aging (AHP).
84. Van Heeringen C., Audenaert K., Van Laere K., Dumont F., Slegers G., Mertens J., and Dierckx R.A. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J. Affect Disord. 74 (2003) 149-158
85. Vastenhouw B., and Beckman F. Sub-millimerter total-body murine imaging with U-SPECT-1. J. Nucl. Med. 48 (2007) 487-493
86. Villemagne V.L., Rowe C.C., Macfarlane S., Novakovic K.E., and Masters C.L. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J. Clin. Neurosci. 12 (2005) 221-230
87. Wang Y., and Tsui B.M. Pinhole SPECT with different data acquisition geometries: usefulness of unified projection operators in homogeneous coordinates. IEEE Trans. Med. Imaging 26 (2007) 298-308
88. Yu T.W., Liu H.M., and Lee W.T. The correlation between motor impairment and cerebral blood flow in Sturge-Weber syndrome. Eur. J. Paediatr. Neurol. 11 (2007) 96-103